Literature DB >> 21316437

Lipid-lowering and antioxidant activities of Jiang-Zhi-Ning in Traditional Chinese Medicine.

Jianxin Chen1, Huihui Zhao, Ying Yang, Bing Liu, Jian Ni, Wei Wang.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Jiang-Zhi-Ning (JZN) is composed of four Chinese herbs, i.e., Fleeceflower Root, Fructus Crataegi, Folium Nelumbinis and Semen Cassiae. It was used to strengthen blood circulation of coronary artery, arrhythmia and hyperlipidemia. AIM OF THE STUDY: The main objective of this paper is to evaluate lipid-lowering and antioxidant activities of extract and effective fraction of JZN by using in vitro experiments on hyperlipidemic rats. Moreover, in vivo experiments on cells were performed to investigate lipid-lowering and antioxidant activities of effective fraction and active constituents of JZN. MATERIALS AND
METHOD: Wistar rats with high fat diet-induced hyperlipidemia were used as in vitro models to study biological effects of lipid-lowering and antioxidant activities of extract and effective fraction of JZN. Serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Coronary Index and Atherogenic Index were investigated to evaluate lipid-lowering effects of extract and effective fraction of JZN. Serum total nitric oxide synthase (NOS), nitric oxide (NO), endothelin-1 (ET-1), malondialdehyde (MDA), superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) were detected to measure antioxidant effects of extract and effective fraction of JZN. Furthermore, oxidized low-density lipoprotein (Ox-LDL) injured human umbilical vein endothelial cell (HUVEC) model was employed as in vivo experiment to study lipid-lowering and antioxidant effects of effective fraction and active constituents of JZN. NO, ET-1, MDA SOD and T-AOC in HUVECs or culture media were investigated to evaluate antioxidant activity of effective fraction and active constituents of JZN. Using human hepatoma cell line Bel-7402, reverse transcription polymerase chain reaction (RT-PCR) technology was performed to investigate cholesterol metabolism effects of effective fraction and active constituents of JZN. Expressions of low density lipoprotein receptor (LDL-R), 3-hydroxy-3-methyl-HMG-coenzyme A reductase (HMG-CoAR), and cholesterol 7α-hydroxylase (CYP7A1) mRNA of the liver cells were investigated to evaluate JZN on associated receptor and enzymes of cholesterol metabolism. High-performance liquid chromatography (HPLC) and spectrophotometry were used to study the impact of effective fraction and active constituents of JZN on synthesis and translation of cholesterol during the process of metabolism by measuring inside and extracellular contents of total bile acid (TBA) of Bel-7402.
RESULTS: Extract and effective fraction of JZN significantly reduced contents of TC, TG and LDL-C, CRI and AI in hyperlipidemic rats as well as significantly increased contents of HDL-C in the rats. Moreover, they significantly enhanced the activity of NOS and increased contents of NO. They also caused significant reductions in contents of ET-1 and MDA as well as significant increase in SOD activity and T-AOC in the hyperlipidemic rats. Several indicators were found to be concentration-dependent. As far as in vivo experiments to investigate biological activities of effective fraction and active constituents of JZN were concerned, it was found that they restored and enhanced the vitality of HUVECs with a concentration-dependent manner as well as content of NO in the culture media of HUVEC. They caused reductions in the contents of ET-1 in the culture media of HUVEC and contents of MDA in HUVECs. They also caused an increase in the vitality of SOD and T-AOC in HUVECs. Furthermore, they enhanced LDL-RmRNA expression, with a concentration-dependent manner. Low and medium concentrations of effective fraction and active constituents of JZN could inhibit expression of HMG-CoAR mRNA. High concentration counterpart could enhance expression of the HMG-CoAR mRNA. They enhanced expression of CYP7A1 mRNA in a concentration-dependent manner. Finally, they caused reductions in the contents of cholesterol in Bel-7402. They also increased intercellular content of total bile acid as well as lowered extracellular contents of TBA in the cells in a concentration-dependent manner.
CONCLUSION: We demonstrated for the first time lipid-lowering and antioxidant activities of extract and effective fractions as well as active constituents of JZN. Active constituents of JZN had the same biological effects with effective fraction and extract of JZN. Therefore, this study supports its ethnopharmacological use in Traditional Chinese Medicine to manage hyperlipidemia and paves a basis for establishing quality control method of Chinese medicine.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316437     DOI: 10.1016/j.jep.2011.01.048

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  13 in total

Review 1.  Clinical study of the hypothesis of endogenous collateral wind on acute coronary syndrome: a review.

Authors:  Xian Wang; Cong Zhang; Ran Yang; Haiyan Zhu; Huaibing Zhao; Xiaoming Li
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

Review 2.  Traditional Chinese medicine for lipid metabolism disorders.

Authors:  Yiping Li; Xiaolong Wang; Zhijie Shen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

3.  Effect of Hedan Tablets on Body Weight and Insulin Resistance in Patients with Metabolic Syndrome.

Authors:  Lian-Yong Liu; Lin Zhou; Xing-Zhen Liu; Da-Jin Zou
Journal:  Obes Facts       Date:  2021-12-30       Impact factor: 4.807

4.  The Beneficial Effects of Edible Kynurenic Acid from Marine Horseshoe Crab (Tachypleus tridentatus) on Obesity, Hyperlipidemia, and Gut Microbiota in High-Fat Diet-Fed Mice.

Authors:  Jian Li; Yaqi Zhang; Shen Yang; Zhenhua Lu; Guiling Li; Shangyi Wu; Da-Ren Wu; Jingwen Liu; Bo Zhou; Hui-Min David Wang; Shi-Ying Huang
Journal:  Oxid Med Cell Longev       Date:  2021-05-03       Impact factor: 6.543

5.  Huangzhi Oral Liquid Prevents Arrhythmias by Upregulating Caspase-3 and Apoptosis Network Proteins in Myocardial Ischemia-Reperfusion Injury in Rats.

Authors:  Xu Ran; Jian Xin Diao; Xue Gang Sun; Ming Wang; Hui An; Guo Qiang Huang; Xiao Shan Zhao; Wen Xiao Ma; Feng Hua Zhou; Yun Gao Yang; Can Ming Miao
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

Review 6.  Chinese herbal medicine on dyslipidemia: progress and perspective.

Authors:  Ming Guo; Yue Liu; Zhu-Ye Gao; Da-Zhuo Shi
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-13       Impact factor: 2.629

7.  The active ingredients of Jiang-Zhi-Ning: study of the Nelumbo nucifera alkaloids and their main bioactive metabolites.

Authors:  Jianxin Chen; Xueling Ma; Kuo Gao; Yong Wang; Huihui Zhao; Hao Wu; Juan Wang; Hua Xie; Yulin OuYang; Liangtao Luo; Shuzhen Guo; Jing Han; Bing Liu; Wei Wang
Journal:  Molecules       Date:  2012-08-16       Impact factor: 4.411

8.  Effects of lipid regulation using raw and processed radix polygoni multiflori in rats fed a high-fat diet.

Authors:  Na Li; Zhen Chen; Xiaojian Mao; Jie Yu; Ronghua Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-09       Impact factor: 2.629

9.  An effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulae.

Authors:  Shaojing Li; Chuanhong Wu; Jianxin Chen; Peng Lu; Chang Chen; Meihong Fu; Jing Fang; Jian Gao; Li Zhu; Rixin Liang; Xin Shen; Hongjun Yang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  Radix Puerariae and Fructus Crataegi mixture inhibits renal injury in type 2 diabetes via decreasing of AKT/PI3K.

Authors:  Zhengyue Chen; Yanyan Yuan; Xinrong Zou; Mengqi Hong; Ming Zhao; Yu Zhao; Yuanping Liu; Guofu Li; Yabin Zhu; Lin Luo; Beiyan Bao; Shizhong Bu
Journal:  BMC Complement Altern Med       Date:  2017-09-08       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.